Johnson’s Managing Director, Nick Franks
Johnson’s Welcomes Government’s Evidence-first Approach To Review Of Over-the-counter Flea Treatments
Johnson’s Veterinary Products (JVP), the family-owned British manufacturer that has helped care for the nation’s pets for more than 100 years, has welcomed the Government’s decision not to back an immediate end to the over-the-counter sale of flea and tick treatments, and is calling for the evidence to lead what happens next.
In its recently published response to the House of Lords Environment and Climate Change Committee, the Government declined to endorse the Committee’s call to end general sale of pet parasite medicines, marking it as pending a review by the Veterinary Medicines Directorate (VMD). It said any change must show “a clear and tangible benefit” for the environment, and must take account of the wider impact on animal welfare, pet owners and businesses.
Every AVM-GSL product is a fully authorised medicine, assessed by the VMD for quality, safety and efficacy before it reaches a shelf, with ongoing monitoring for as long as it is sold. The principle is the same one that lets people buy paracetamol or aspirin from a local shop: the level of control matches the level of risk.
The VMD’s review, which covers products containing fipronil or imidacloprid, follows concerns about residues in English waterways. A summary of responses to its call for evidence is due imminently. JVP takes the problem seriously and supports further research, but argues that moving products behind the counter and restricting access is not a proven answer.
The Government also cited the Competition and Markets Authority’s review of the veterinary market. Its final report in March found that some parasiticides have safety records strong enough to support less restrictive categories and urged measures to widen access.
Independent retailers say the stakes for them are high. In a snap JVP survey of 25 independent pet shops, 76% said reclassification would make it unlikely or impossible to keep stocking flea and tick treatments. Only three had a qualified SQP in store.
Jordan Ham of The Pet Centre Truro said: “The loss of being able to stock these products would have an immediate, significant negative impact on our business and many like us. Small businesses could be lost from high streets.”
Pet owners would feel it too. Censuswide research for JVP found that 43% would visit their local pet shop less often or stop altogether if current flea treatments were no longer available there.
Johnson’s Managing Director, Nick Franks, commented: “The Government is right that any change must be backed by evidence of real benefit. For more than 20 years, AVM-GSL has struck the right balance between proper regulation and affordable pet care. If new evidence shows more controls should be considered, it must be weighed carefully.
“But established medicines with a long safety record shouldn’t face new restrictions without a full assessment of what that would mean for pets, owners and the shops that serve them. Make treatment harder to find and more expensive, and some pets simply won’t get treated. Nobody on any side of this debate wants that.”
More from Johnson’s Veterinary Products
- Flea treatment restrictions would hit lower-income pet owners hardest
- Quality tops the list as pet owners reveal what matters most when choosing products for their animals
- Love your local pet shop? New research says it's time to prove it
- Johnson's expands popular joint health range with cat mobility in mind
- Johnson’s Scoops Supplier of the Year Prize at Prestigious Industry Awards
2 days ago
157 views

15 hours ago